Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome

Status Recruiting

Clinical Trial Summary

The investigators designed a compassionate basis phase II study for refractory/relapsed mycosis fungoides/Sezary syndrome consisting of alemtuzumab (Campath) for primary evaluation of overall response and time to relapse. Other goals to consider are toxicity and time to new therapy.

Clinical Trial Description

- 20 relapsed or refractory advanced mycosis fungoides/Sezary syndrome patients are scheduled with gradually escalated doses (3 mg, 10 mg , and 30 mg) on sequential days during the first week, followed by 30 mg three times a week until 12 weeks.

- Patients must have serology negative for human T-lymphotropic virus 1 (HTLV-1) and until three different regimens of chemotherapy.

- Follow up for one year after last cycle of alemtuzumab. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00157274
Study type	Interventional
Source	Latin American Cooperative Onco-Haematology Group - Peru
Contact	Julia M Huamani, MD
Phone	511-2227020
Email	juliahuamaniz@yahoo.es
Status	Recruiting
Phase	Phase 2
Start date	July 2005
Completion date	July 2008

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT02881749` - Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides	Phase 2
Terminated	`NCT02890368` - Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides	Phase 1
Completed	`NCT00051012` - Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients	Phase 4
Terminated	`NCT03789864` - Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides	N/A
Completed	`NCT01590732` - Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma	Phase 1
Recruiting	`NCT02848274` - ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
Recruiting	`NCT00177268` - Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Recruiting	`NCT05357794` - Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides	Phase 2
Completed	`NCT04955340` - A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat	Phase 1
Recruiting	`NCT04960618` - Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome	Phase 2
Completed	`NCT02883517` - Cell-free Circulating DNA in Primary Cutaneous Lymphomas
Active, not recruiting	`NCT02953301` - Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)	Phase 2
Completed	`NCT00254332` - Effect of Denileukin Diftitox on Immune System in CTCL Patients	N/A
Completed	`NCT02296164` - Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma
Recruiting	`NCT05680558` - Photopheresis in Early-stage Mycosis Fungoides	Phase 2
Completed	`NCT00038376` - Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies	Phase 2
Completed	`NCT00168064` - Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides	Phase 2
Recruiting	`NCT05879458` - Ritlecitinib in CTCL	Phase 2
Recruiting	`NCT05414500` - Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides	Phase 1
Recruiting	`NCT05904522` - Histopathological Changes in Mycosis Fungoides	N/A